In a surprising move that has abortion advocates scrambling, Health and Human Services Secretary Robert F. Kennedy Jr. announced Wednesday that he has ordered a *complete review* of the chemical abortion pill mifepristone, following bombshell revelations that the drug may be far more dangerous than advertised.
“It’s alarming,” Kennedy told the Senate Health, Labor, Education and Pensions Committee during a hearing. The source of his concern? A new study from the conservative Ethics & Public Policy Center (EPPC) that analyzed over **865,000 abortion cases** and found that *nearly 11%* of women who took mifepristone experienced serious adverse health effects—including sepsis, infections, hemorrhaging, and other complications.
For a drug that the FDA has long claimed is “safe,” the numbers are staggering. Senator Josh Hawley (R-Mo.) grilled Kennedy on the report, pointing out that the real rate of complications is **22 times higher** than what the FDA’s label currently suggests—just 0.5%. Kennedy agreed that the label is likely outdated and inadequate: “Clearly [the study] indicates, at the very least, that the label should be changed.”
This isn’t just about labels, though. The FDA originally approved mifepristone in 2000 under a cloud of political pressure. Since then, Democrats have worked steadily to expand its reach. Under Barack Obama, the pill’s use was extended from seven to ten weeks of pregnancy. Then, in a dangerous move under Joe Biden, the FDA allowed mifepristone to be prescribed *online* and shipped *by mail*, bypassing in-person doctor visits entirely—a decision the Supreme Court inexplicably upheld in a unanimous ruling last year.
Now, reality may finally be catching up to the pro-abortion narrative.
The EPPC, a D.C.-based think tank grounded in Judeo-Christian principles, released its findings last month, warning that mifepristone’s health risks are *not* being accurately reported or responsibly managed. The group urged the FDA to tighten its safety protocols and consider revoking the drug’s approval altogether.
“The FDA should further investigate the harm mifepristone causes to women and, based on objective safety criteria, reconsider its approval altogether,” the report concluded.
That’s exactly what RFK Jr. is now asking his FDA director, Dr. Marty Makary, to do: conduct a full investigation and report back. It’s a bold step for a health secretary in a Democrat administration, and one that may signal a shift toward putting women’s health and safety ahead of political agendas.
For years, the left has peddled abortion pills as a safe, convenient, and empowering option. But this latest data tells a different story—one of risk, trauma, and misleading information. When over 1 in 10 women are suffering serious side effects, that’s not “safe and effective.” That’s a public health crisis.
It’s time the FDA faces the facts and stops serving the abortion industry’s interests. And if RFK Jr. follows through, he might do more to protect American women than any Democrat has in decades.
